11 June 2025 - AbbVie Korea's Epkinly (epcoritamab), a treatment for adults with relapsed or refractory diffuse large B-cell lymphoma after two or more systemic therapies, has passed the review of the Cancer Disease Review Committee, the first gateway to reimbursement.

However, Janssen Korea's Tecvayli (teclistamab), a novel bispecific antibody that dual targets B-cell maturation antigen and the T-cell receptor CD3 in treating relapsed multiple myeloma, failed to set the reimbursement criteria.

Read Korea Biomedical Review article